human ig lambda light chain antibody  (R&D Systems)

Journal: iScience

Article Title: Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron

doi: 10.1016/j.isci.2023.106323

Figure Lengend Snippet:

Article Snippet: Anti-Lambda-PE (clone IS7-24C) , Miltenyi Biotec , Cat# 130-119-778; RRID: AB_2751837.

Techniques: Virus, Recombinant, Blocking Assay, Saline, Enzyme-linked Immunosorbent Assay, Membrane, Plasmid Preparation, Expressing, Software

Journal: PLoS Pathogens

Article Title: Hantavirus infection-induced B cell activation elevates free light chains levels in circulation

doi: 10.1371/journal.ppat.1009843

Figure Lengend Snippet: B cells were enriched from blood of 3 healthy volunteers and infected with live or UV-inactivated purified PUUV, together with Sendai and Sindbis viruses, for comparison (multiplicity of infections for all viruses equals 1). The TLR9 agonist CpG and no treatment were used as a positive and negative controls for B cell activation, respectively. After culturing for 8 days, kappa and lambda FLCs in (A) and IgA, IgM and IgGs in (B) were measured from cell supernatants. Remaining cells were subjected to IgA, IgM and IgG-specific antibody secreting cell (ASC) quantification using Elispot. IgA + and IgM + ASCs were simultaneously detected in one well, using AP-conjugated anti-IgA and HRP-conjugated anti-IgM Abs, and IgG + ASCs in a separate well using HRP-conjugated anti-IgG Ab. Representative Elispot images from one donor are shown in (C), and ASC quantification per input cell number measured from all donors in (D). Significant differences of each treatment group, as compared to non-treated cells, were assessed using two-way ANOVA and Dunnett’s multiple comparison tests. *p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: The following mAbs were used: anti-kappa light chain PercP-Cy5.5 (G20-193), anti-lambda light chain BV605 (JDC-12), anti-IgM APC (G20-127), anti-IgG AF700 (G18-145; all from BD) and anti-IgA PE-Vio770 (IS11-8E10; Miltenyi).

Techniques: Infection, Purification, Comparison, Activation Assay, Enzyme-linked Immunospot

Journal: Blood Cancer Journal

Article Title: Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

doi: 10.1038/s41408-020-00393-0

Figure Lengend Snippet: a Western blot analysis of ubiquitinated proteins in total protein lysates extracted from LP1 and RPMI8226 PA28α knockdown stable cells. β-actin as a loading control. b OPP pulse-chase assay of proteasome degradation and protein synthesis in LP1 PA28α knockdown stable cells. Western blot analysis of immunoglobulin lambda light chain (ƛ IgL) ( c ), eIF2α, p62/SQSTM1, and LC3B ( d ) in LP1 and RPMI8226 PA28α knockdown stable cells, β-actin as a loading control. ** P < 0.01, Student’s t test. e Working model of PA28α knockdown in MM.

Article Snippet: Antibodies used were as follows: PA28α (Cell Signaling), PSMA2 (Cell Signaling), S5a (Cell signaling), PA28β (Cell Signaling), Phospho-eIF2α (Ser51) (Cell signaling), eIF2α (Cell signaling), α-tubulin (Genetex), PA28γ (Genetex), PSMB5 (Genetex), PSMB6 (Enzo life science), PSMB7 (Genetex), PSMB8 (Genetex), PSMB9 (R&D systems), PSMB10 (R&D systems), Rpt5 (Enzo life science), Ubiquitin (Cell Signaling), β-actin (Santa Cruz Technology), TCF11/NRF1 (Cell Signaling), LC3B (Cell Signaling), p62/SQSTM1 (MBL International) human Ig lambda light chain (R&D systems), actin (Sigma). pLKO.1 empty vector, shRNA vector targeting human PA28α, NRF1 siRNA (ON-TARGETplus SMARTpool), PA28α siRNA (Accell SMARTpool), and control siRNA were purchased from Dharmacon.

Techniques: Western Blot, Knockdown, Control, Pulse Chase

Journal: Cell

Article Title: Slow delivery immunization enhances HIV neutralizing antibody and germinal center responses via modulation of immunodominance

doi: 10.1016/j.cell.2019.04.012

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Mouse anti-human Lambda biotin (Clone: IS7–24C7) , Miltenyi , Cat # 130–093-025.

Techniques: Virus, Recombinant, Produced, Staining, Chromogenic LAL Assay, Quantitation Assay, Real-time Polymerase Chain Reaction, Sequencing, Software, Binding Assay